- Allogene Therapeutics (NASDAQ:ALLO) -36% following clinical hold on AlloCAR T trials
- Cellectis (NASDAQ:CLLS) -20%.
- Cidara Therapeutics (NASDAQ:CDTX) -18% on launching stock and preferred stock offerings
- MaxCyte (NASDAQ:MXCT) -12%.
- Rocket Lab (NASDAQ:RKLB) -10%.
- Verb Technology (NASDAQ:VERB) -9%.
- Cemtrex (NASDAQ:CETX) -8%.
- Superior Drilling Products (NYSE:SDPI) -5%.